Sino Biopharmaceutical (HKG:1177) unit Beijing Tide Pharmaceutical's Second-Generation Flurbiprofen Patch obtained marketing approval from China's National Medical Products Administration, according to a Thursday Hong Kong bourse filing.
The approval is for the indications of analgesia and anti-inflammatory treatment for osteoarthritis, shoulder periarthritis, tendinitis and tenosynovitis, peritendinitis, lateral epicondylitis, muscle pain, and swelling and pain due to trauma.
The product was also granted a four-year data protection period by the regulator.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments